Israel Active

Israel’s Zebra Medical Vision (reported previously) has partnered with American radiology system distributor, Canon Medical Systems USA (part of the Canon empire). Zebra’s disease analysis platform will be made available to many more locations across the United States.

The vital signs monitoring tool from Israel’s Binah.ai (reported previously) is to be used by 4 Japanese companies. NTT Data - Health Data Bank; Alm’s MySOS - emergencies & new Covid-19 cases; Macnica Networks – monitoring Covid-19 re-infections; SOMPO – insurance policyholder checkups.

Kibbutz Hatzerim is famous for founding drip-irrigation innovator Netafim. It has now co-founded Picodya - developer of the B-Matrix in vitro diagnostics (IVD) platform. B-Matrix gives 15-30min test results for cancer, cardiac dysfunction and viruses (including Covid).

Israel-headquartered Lumenis (reported previously) has launched a superior version 2.0 of its Moses platform for minimal and non-invasive laser removal of urinary (bladder) stones and other stones.

Tel Aviv University researchers reduced secondary cancer following colorectal tumor removal. Deralin and Etopan were given before and after surgery. 3 years later the cancer had spread significantly less than in a control group. Now pancreatic cancer patients will be tested. (latest trial) (2017 trial on breast cancer patients)

Israel’s KAHR Medical has received US FDA approval to begin Phase 1 & 2 clinical (human) trials of its DSP107 treatment of advanced solid tumors (reported previously). The trials will assess DSP107 both by itself and in combination with Roche’s atezolizumab.

This 30-minute video features Israel’s Dr. Tal Zaks - chief medical officer of Moderna, a front-runner in the race for a COVID-19 vaccine. He summarizes the progress of the latest trial, and how his education at BGU’s Joyce and Irving Goldman Medical School shaped his career.

Professor Zeev Rotstein, CEO of Jerusalem’s Hadassah Medical Center, has revealed that its clinic in Skolkovo, Moscow is involved in clinical safety trials of the new Russian Covid-19 vaccine. Phase 3 trials are still ongoing, even while Russia’s President Putin inoculated his family.

Researchers at Israel’s Ben Gurion and Hebrew Universities have found that vaccinations given against Tuberculosis (BCGs) in the last 15 years reduced death rates and infection rates in COVID-19 patients under 24 years of age. Data from 55 countries was analyzed.

Israel’s Pluristem Therapeutics (reported previously) has been approved by German’s health regulatory authority to conduct a Phase 2 clinical trial of its PLX PAD stem cells on 40 serious Covid-19 patients. Pluristem is already conducting a 140-patient Phase 2 trial in the US.